Patients Characteristics

Surgery+ adjuvant chemotherapy
(n=39)

Chemoradiation alone   (n=36)

AGE, years

60 (56.1-62.0)

63 (58.7-63.9)

GENDER

male

35 (90%)

34 (94%)

female

4 (10%)

2 (6%)

HISTOLOGY

Adenocarcinoma

14 (36%)

12 (34%)

Squamous

18 (46%)

21(58%)

other

7 (18%)

3 (8%)

STAGE/TNM

T4N0

2 (5%)

2 (6%)

T3N1

13 (34%)

5 (14%)

T4N1

4 (10%)

10 (27%)

T1N2

2 (5%)

2(6%)

T2N2

18 (46%)

17(47%)

TYPE OF SURGERY

Lob/bilobectomy

15(39%)

Pneumonectomy

24 (61%)

CHEMOTHERAPY REGIMEN

Cisplatin/Etoposide

22 (61%)

Carboplatin/Paclitaxel

14 (39%)

PERFORMANCE STATUS

ECOG 0-1

36 (92%)

32(89%)

ECOG 2

3 (8%)

4(11%)

Survival Time

Surgery+ adjuvant chemotherapy
(n=39)

Chemoradiation alone                (n=36)

P-value

1-year

69%

64%

p= 0.623

Surgery+ adjuvant chemotherapy
(n=39)

Chemoradiation alone (n=36)

Haematological

Anaemia   Grade >2

  7 (17.9%)

6 (16.6%)

Thrombocytopenia Grade >2

2 (5.1%)

3 (8.3%)

Febrile neutropenia

0

3 (8.3%)

Non-Haematological

Fatigue

N/A

12 (33.3%)

Neuropathy

0

7 (19.4%)

Cardiac

3 (7.6%)

6 (16.6%)

GI complications

2 (5.1%)

12 (33.3%)

Pneumonitis Grade >2

0

10 (27.7%)

Thromboembolic event

 4 (10.2%)

3 (8.3%)

Esophagitis Grade 2-3

0

16(44.4%)

Treatment-related death

3 (7.6%)

2 (5.5%)